A review of data from both the MARINE and ANCHOR trials reveals that a new prescription omega-3 product available in the US significantly reduces inflammatory biomarkers. This pure ethyl ester EPA product (trade name Vascepa) is approved for lowering triglycerides in patients with triglycerides >500mg/dL. Unlike other fish oil products that have both EPA and DHA, this EPA only product lowers Apo B and non-HDL-C without increasing LDL-C. A review of this EPA only product published in the Am J Cardiovasc Drugs reveals that, in patients with severe hypertriglyceridemia, the standard dose of 4g/day significantly lowers oxidized low-density lipoprotein (OxLDL), high-sensitivity C-reactive protein (hsCRP), and lipoprotein-associated phospholipase A2 (Lp-PLA2). OxLDL was lowered 13%, hsCRP 22-36% and Lp-PLA2 22-36% in these trials.
Reference: Bays HE, Ballantyne CM, Braeckman RA, et al. Icosapent ethyl, a pure ester of eicosapentaenoic acid: Effects on circulating markers of inflammation from the MARINE and ANCHOR studies. Am J Cardiovasc Drugs 2013; 13:37-46. DOI 10.1007/s40256-012-0002-3